Drugs / Kylo-0603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06365580 | May 2023 → Aug 2024 | metabolic dysfunction-associated steatohepatitis | Kylonova (Xiamen) Biopharma co., LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kylo-0603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06365580 ↗ |
| Route | Oral | “Administrated orally.” NCT06365580 ↗ |